Navigation Links
By 2018, GlaxoSmithKline's Votrient Will Garner Sales of $640 Million and Will Overtake Pfizer's Sutent as the Renal Cell Carcinoma Market Leader
Date:9/14/2009

WALTHAM, Mass., Sept.14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.

The new Pharmacor report entitled Renal Cell Carcinoma finds that Votrient will overtake Sutent as the renal cell carcinoma market leader by 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. For the treatment of renal cell carcinoma, Votrient is expected to launch in the U.S. in 2010, in Europe in 2011 and in Japan in 2012. According to the report, the angiogenesis inhibitor drug class will continue to dominate this market over the next decade, capturing 87 percent of total sales in 2018.

The report also finds that Novartis's Afinitor and Pfizer's axitinib will surpass Bayer Healthcare/Onyx's Nexavar and Wyeth's Torisel by 2018 in the second- and third-line treatment settings. In 2008, Nexavar was the leading therapy in the second-line setting and Torisel was the leading therapy in the third-line setting for the treatment of renal cell carcinoma.

"Thought leaders we interviewed indicate that they are optimistic about several emerging therapies, most notably axitinib and Votrient," said Decision Resources Analyst Karen Pomeranz, M.Sc., Ph.D. "One expert called axitinib 'the most exciting' emerging agent in renal cell carcinoma in recent years and another thought leader said that Votrient's clinical efficacy is comparable to that of Sutent and that Votrient has a more favorable side-effect profile than Sutent."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources         Decision Resources, Inc.
    Christopher Comfort        Elizabeth Marshall
    781-296-2597               781-296-2563
    ccomfort@dresources.com    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Masimo Rad-87(R) Pulse CO-Oximeter(TM) Garners Silver 2009 Medical Design Excellence Award
2. CyberKnife Center of Miami Executive Director James G. Schwade M.D. Garners Ultimate Miami CEO Award
3. AST Leaders Fly to Capitol Hill to Garner and Secure Support for Transplantation Initiatives
4. Tray-Pak Direct Mailer Garners 21% Response, Design Award
5. Absolutely PR's Maggie Holben Participates In CBSA BioBreakfast Expert Panel "How to Garner Media Attention & Effectively Use Public Relations Tactics"
6. Novel Anticoagulants Will Garner More Than Three-Quarters of the Atrial Fibrillation Drug Market in 2017
7. Novel IBS treatment developed at UB garners $8.5 million for seven-year clinical trial
8. Performance Health Technologies Garners Additional Media Coverage, Including Scientific Americans News Blog
9. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
10. Rising Garners Top Honors on the Private Company Indexs Top Five Growth Companies List for Q1 2008
11. Study garners unique mating photos of wild gorillas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... Dr. Benjamin ... in non-surgical hair loss treatment. Dr. Stong is double board certified and the ... for the treatment of hair loss. Non-surgical therapies such as stem cells can ...
(Date:5/5/2016)... San Rafael, CA (PRWEB) , ... May 05, 2016 , ... ... Coach of the Year, Derek Pittman, along with his university coaching staff. Together they ... and girls, with separate sessions run for youth players ages 5-13, and high school ...
(Date:5/5/2016)... CA (PRWEB) , ... May 05, 2016 , ... ... may not seem like an intuitive activity to alleviate the pain that’s a ... effective in improving pain and function in people with arthritis. , “Physical ...
(Date:5/5/2016)... , ... May 05, 2016 , ... The Lung Institute will celebrate its ... a seminar at most clinic locations throughout the month of May. To date, the Lung ... “The rapid growth that we’ve seen is a testament to the success of this treatment ...
(Date:5/5/2016)... N.J. (PRWEB) , ... May 05, 2016 , ... ... patients with cancer, today announced a new collaboration with Imerman Angels to ... cancer anywhere in the world. , “Imerman Angels provides an emotional lifeline to patients ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... TUCSON, Ariz. , May 3, 2016  As ... twice contracted rheumatic fever, which damaged his heart. ... But by June 2013, Shepherd,s heart was ... days from death. On June 20, 2013, the ... temporary Total Artificial Heart (TAH-t). Like a heart transplant, ...
(Date:5/3/2016)... , May 3, 2016  While you may be familiar with watching a film or ... also known as ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a renowned authorized ... innovative technology. Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... , May 3, 2016 Pharmaceutical ... $55 million to a woman who says its talc-based ... awarded Gloria Ristesund $5 million in compensatory ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... against the company. In February, the same court awarded ...
Breaking Medicine Technology: